BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35595822)

  • 1. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
    Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
    Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
    Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
    Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
    Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
    Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
    Shi F; Su J; Wang J; Liu Z; Wang T
    Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
    Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
    ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.
    Wang X; Huang R; Wu W; Xiong J; Wen Q; Zeng Y; Chen T; Li J; Zhang C; Zhong JF; Yang S; Zhang X
    Acta Biomater; 2023 Feb; 157():381-394. PubMed ID: 36375786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity.
    Pei J; Zhang Y; Luo Q; Zheng W; Li W; Zeng X; Li Q; Quan J
    Cancer Lett; 2019 May; 450():110-122. PubMed ID: 30790684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
    Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
    Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
    Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
    Front Oncol; 2021; 11():621550. PubMed ID: 33777767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
    Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
    Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Non-Nucleotide Small-Molecule STING Agonists
    Cherney EC; Zhang L; Lo J; Huynh T; Wei D; Ahuja V; Quesnelle C; Schieven GL; Futran A; Locke GA; Lin Z; Monereau L; Chaudhry C; Blum J; Li S; Fereshteh M; Li-Wang B; Gangwar S; Pan C; Chong C; Zhu X; Posy SL; Sack JS; Zhang P; Ruzanov M; Harner M; Akhtar F; Schroeder GM; Vite G; Fink B
    J Med Chem; 2022 Feb; 65(4):3518-3538. PubMed ID: 35108011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 17. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia.
    Aikins ME; Sun X; Dobson H; Zhou X; Xu Y; Lei YL; Moon JJ
    J Control Release; 2024 Apr; 368():768-779. PubMed ID: 38492861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
    Shen A; Li X; Zhang Y; Ma J; Xiao R; Wang X; Song Z; Liu Z; Geng M; Zhang A; Xie Z; Ding C
    Eur J Med Chem; 2022 Nov; 241():114627. PubMed ID: 35963129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.
    Yin M; Hu J; Yuan Z; Luo G; Yao J; Wang R; Liu D; Cao B; Wu W; Hu Z
    Cell Cycle; 2022 Apr; 21(8):767-779. PubMed ID: 35130108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS).
    Messaoud-Nacer Y; Culerier E; Rose S; Maillet I; Rouxel N; Briault S; Ryffel B; Quesniaux VFJ; Togbe D
    Cell Death Dis; 2022 Mar; 13(3):269. PubMed ID: 35338116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.